Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1991 Mar;33(2):71–79. doi: 10.1007/BF01742532

Modulation of the immune response to tumors by a novel synthetic compound, (4R)-3-benzoyl-N-[(1R)-1-phenylethyl]-4-thiazolidinecarboxamide (RS-0481)

Shinichi Kurakata 1,✉, Mikiko Tomatsu 1, Miyuki Arai 1, Harumi Arai 1, Atsushi Hishinuma 1, Hiroko Kohno 1, Kouichi Kitamura 2, Tomowo Kobayashi 1, Kikuo Nomoto 3
PMCID: PMC11038599  PMID: 1828007

Abstract

RS-0481, (4R)-3-benzoyl-N-[(1R)-phenylethyl]-4-thiazolidinecarboxamide, is a compound that can re-establish the function of certain lymphoid cell populations impaired by the presence of a growing tumor in an animal. The compound markedly augmented the tumorspecific cytotoxic T lymphocytes,Tdth (delayed-type hypersensitivity T cells), and the nonspecific lymphokine-activated-killer-cell-like cell responses. It also enhanced the tumor-inhibitory effect of macrophages in tumor-bearing mice, but not in normal mice, indicating that it enhances the antitumor immune responses. Lymphocytes from RS-0481-treated tumor-bearing mice released significantly higher amounts of macrophage-activating factor(s) (MAF) and interleukin-2(IL-2)-like factors in culture compared with lymphocytes from untreated animals. Also, sera from treated tumor bearers showed elevated colony-stimulating factor (CSF) activity. Although the compound did not influence the factor-producing activity in mice without tumor, it enhanced the responsiveness of their bone marrow cells, T cells, and macrophages to CSF, IL-2, and MAF. It seems therefore possible that the compound enhances the responsiveness of immunocompetent cells to cytokines, resulting in a marked augmentation of antitumor T cell responses in tumor-bearing mice. Consistently it inhibited the development of lymph node metastasis of transplanted X5563 plasmacytoma, and we showed that T cells play a decisive role in this inhibition. The compound also counteracted the development of suppressor T cell activity in the spleen of tumor-bearing mice.

Key words: Tumor immunity, X5563 plasmacytoma, Biological response modifiers, Thiazolidine immunomodulator, Cytokine responsiveness

References

  • 1.Burger CJ, Elgert KO, Farrar WL. Interleukin 2 (IL-2) activity during tumor growth: IL-2 production kinetics, absorption of and responses to exogenous IL-2. Cell Immunol. 1984;84:228. doi: 10.1016/0008-8749(84)90095-9. [DOI] [PubMed] [Google Scholar]
  • 2.Burnet FM. Immunological surveillance in neoplasia. Transplant Rev. 1977;7:3. doi: 10.1111/j.1600-065x.1971.tb00461.x. [DOI] [PubMed] [Google Scholar]
  • 3.Chow DA, Green MI, Greenberg AH. Macrophage-dependent, NK-cell-independent “natural” surveillance of tumors in syngeneic mice. Int J Cancer. 1979;23:788. doi: 10.1002/ijc.2910230609. [DOI] [PubMed] [Google Scholar]
  • 4.Eilber FR, Morton DL. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer. 1970;25:362. doi: 10.1002/1097-0142(197002)25:2<362::aid-cncr2820250213>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  • 5.Fujiwara H, Hamaoka T, Shearer GM, Yamamoto H, Terry WD. The augmentation of in vitro and in vivo tumor-specific T cell-mediated immunity by amplifier T lymphocytes. J Immunol. 1980;124:863. [PubMed] [Google Scholar]
  • 6.Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T. The role of tumor-specific Lyt-1+2− T cells in eradicating tumor cells in vivo. I. Lyt-1+2− T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity. J Immunol. 1984;133:1671. [PubMed] [Google Scholar]
  • 7.Furukawa H, Fujiwara H, Yoshioka T, Itoh K, Hamaoka T. Tumor-specific Lyt-1+2− T cells can reject tumor cells in vivo without inducing cytotoxic T lymphocyte responses. Transplant Proc. 1985;17:599. [Google Scholar]
  • 8.Haraguchi S, Kurakata S, Fujii T, Matsuo T, Yoshida TO. Recognition of Rous sarcoma virus-induced tumor antigens by cytotoxic T lymphocytes (CTL): studies on specificity of killing by CTL employing H-2 congenic and recombinant mouse tumor cells. Cell Immunol. 1987;105:340. doi: 10.1016/0008-8749(87)90082-7. [DOI] [PubMed] [Google Scholar]
  • 9.Haskell CM. Immunologic aspects of cancer chemotherapy. Annu Rev Pharmacol Toxicol. 1977;17:179. doi: 10.1146/annurev.pa.17.040177.001143. [DOI] [PubMed] [Google Scholar]
  • 10.Kärre K, Seeley JK. Cytotoxic Thy 1.2-positive blasts with NK-like target selectivity in murine mixed lymphocyte cultures. J Immunol. 1979;123:1511. [PubMed] [Google Scholar]
  • 11.Kennard J, Zolla-Pazner S. Origin and function of suppressor macrophages in myeloma. J Immunol. 1980;124:268. [PubMed] [Google Scholar]
  • 12.Klein E, Masucci MG, Berthold W, Blazar BA. Lymphocytemediated cytotoxicity toward virus-induced tumor cells; natural and activated killer lymphocytes in man. Cold Spring Harbor Conf Cell Proliferation. 1980;7:1187. [Google Scholar]
  • 13.Kniep EM, Domzig W, Lohmann-Matthes ML, Kickhofen B. Partial purification and chemical characterization of macrophage cytotoxicity factor (MCF, MAF) and its separation from migration inhibitory factor (MIF) J Immunol. 1981;127:417. [PubMed] [Google Scholar]
  • 14.Kurakata S, Kitamura K. Suppressor cells in levamisoletreated mice: a possible role of T-cell-mediated feedback suppression in the drug-induced suppression of the humoral immune response. Immunopharmacology. 1983;6:259. doi: 10.1016/0162-3109(83)90034-6. [DOI] [PubMed] [Google Scholar]
  • 15.Kwong L, Kilburn DG, Teh H-S. The use of cytotoxic T cells in the regulation of tumor growth in syngeneic mice. Cancer Immunol Immunother. 1984;17:205. doi: 10.1007/BF00205487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Lotze MT, Robb RJ, Sharrow SO, Frana LW, Rosenberg SA. Systemic administration of interleukin-2 in humans. J Biol Response Mod. 1984;3:475. [PubMed] [Google Scholar]
  • 17.Louie A, Gallagher J, Sikora K, Levy R, Rosenberg SA, Merigan T. Follow up observations on the effect of human leukocyte interferon on non-Hodgkin's lymphoma. Blood. 1981;58:712. [PubMed] [Google Scholar]
  • 18.Nagano M, Sakai J, Saito A, Sato S, Ikeda T, Iwabuchi H, Nakamura K. The syntheses of a novel host mediated antitumor activator, RS-0481, and its metabolites in the rat and dog. Annu Rep Sankyo Res Lab. 1990;42:41. [Google Scholar]
  • 19.Nakajima H, Fujiwara H, Takai Y, Izumi Y, Sano S, Tsuchida T, Hamaoka T. Studies on macrophage-activating factor (MAF) in anti-tumor immune responses: I. Tumor-specific Lyt-1+2− T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages. J Immunol. 1985;135:2199. [PubMed] [Google Scholar]
  • 20.Nishimura T, Hashimoto Y. Induction of nonspecific killer T cells from non-immune mouse spleen cells by culture with interleukin 2. Jpn J Cancer Res (Gann) 1984;75:177. [PubMed] [Google Scholar]
  • 21.North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982;55:1063. doi: 10.1084/jem.155.4.1063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.North RJ. The murine antitumor immune response and its therapeutic manipulation. Adv Immunol. 1984;35:89. doi: 10.1016/s0065-2776(08)60575-1. [DOI] [PubMed] [Google Scholar]
  • 23.Otter WD. Immune surveillance and natural resistance: an evaluation. Cancer Immunol Immunother. 1986;21:85. doi: 10.1007/BF00199854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Rosenstein M, Yron I, Kaufmann Y, Rosenberg SA. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in Interleukin 2. Cancer Res. 1984;44:1946. [PubMed] [Google Scholar]
  • 25.Vose BM, Vánky F, Argov S, Klein E. Natural cytotoxicity in man: activity of lymph node and tumor-infiltrating lymphocytes. Eur J Immunol. 1977;7:753. doi: 10.1002/eji.1830071102. [DOI] [PubMed] [Google Scholar]
  • 26.Warner JF, Dennert G. Effects of a cloned cell line with NK activity on bone marrow transplants, tumor development and metastasis in vivo. Nature. 1982;300:31. doi: 10.1038/300031a0. [DOI] [PubMed] [Google Scholar]
  • 27.Yamauchi K, Fujimoto S, Tada T. Differential activation of cytotoxic and suppressor T cells against syngeneic tumors in the mice. J Immunol. 1979;123:1653. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES